Posted: July 3rd, 2013 | Author: Michael Courtenay | Filed under: Medicated | Tags: AIDS Research, Harvard Medical School, HIV AIDS, HIV Cure, Stem Cell Therapy, The Berlin Patient | Comments Off on Stem-cell Therapy Extirpates HIV
US researchers have revealed that two patients appear to have become completely Human Immunodeficiency Virus – HIV – free after having bone marrow stem cell transplants.
HIV differs from many viruses in that it has very high genetic variability. HIVs diversity is a result of it’s super-fast replication cycle, with a generation of about 1010 virions every day. This complex killer has so many variants that many scientists believed that it was almost incurable.
Both HIV free patients had received stem-cell transplants after developing lymphoma, a type of blood cancer. The patients had been undergoing long-term drug therapy to control HIV.
The Harvard Medical School’s Timothy Henrich says doctors have been unable to find any evidence of the HIV infection in the men since the transplants :: Read the full article »»»»
Posted: January 25th, 2012 | Author: Michael Courtenay | Filed under: Favorite New Thought, From The Web | Tags: Cankler Science News, Favorite New Thought, Human Embryonic Stem Cell Therapy, Stem Cell Therapy | Comments Off on Early Promise For Human Embryonic Stem Cell Therapy
Nature Blogs is reporting that 2 clinical trials testing retinal cells derived from human embryonic stem cells are showing positive preliminary results. A paper published in The Lancet says that the cells appear to be safe four months after being injected into the eyes of two blind patients and describes visual improvements in the patients.
This isn’t the first trial of therapies based on human embryonic stem cells, nor does it provide the first data on these therapies in humans. It does, however, provide the first — albeit early — data from the only ongoing clinical trial of such a treatment. One trial involves patients with ‘dry’ age-related macular degeneration – AMD – the leading cause of blindness in the developed world, whereas the other is focused a juvenile form of degenerative blindness called Stargardt’s macular dystrophy. Neither condition is treatable.
The reported results are from the first patient from each of the two trials, both of which will eventually enrol a dozen patients. Final results are expected in 2013. The early-stage safety trials are sponsored by Advanced Cell Technology, a stem-cell firm in Marlborough, Massachusetts (see ‘Never say die’, a recent News Feature about Advanced Cell Technology).